Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 45,000 shares of the stock in a transaction dated Monday, July 24th. The stock was bought at an average price of $6.42 per share, with a total value of $288,900.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $19,702,665.42. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, August 2nd, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The shares were acquired at an average price of $6.15 per share, with a total value of $153,750.00.
  • On Tuesday, August 1st, Phillip Md Et Al Frost purchased 46,600 shares of Opko Health stock. The shares were acquired at an average price of $6.25 per share, with a total value of $291,250.00.
  • On Friday, July 28th, Phillip Md Et Al Frost purchased 35,100 shares of Opko Health stock. The shares were acquired at an average price of $6.30 per share, with a total value of $221,130.00.
  • On Thursday, July 27th, Phillip Md Et Al Frost purchased 23,600 shares of Opko Health stock. The shares were acquired at an average price of $6.34 per share, with a total value of $149,624.00.
  • On Wednesday, July 26th, Phillip Md Et Al Frost purchased 36,200 shares of Opko Health stock. The shares were acquired at an average price of $6.39 per share, with a total value of $231,318.00.
  • On Tuesday, July 25th, Phillip Md Et Al Frost purchased 39,800 shares of Opko Health stock. The shares were acquired at an average price of $6.41 per share, with a total value of $255,118.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were acquired at an average price of $6.46 per share, with a total value of $34,884.00.
  • On Monday, July 17th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was purchased at an average price of $6.04 per share, with a total value of $10,872.00.
  • On Friday, July 14th, Phillip Md Et Al Frost bought 12,600 shares of Opko Health stock. The stock was purchased at an average price of $6.16 per share, with a total value of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The stock was purchased at an average price of $6.12 per share, with a total value of $22,032.00.

Opko Health, Inc. (NASDAQ:OPK) opened at 6.32 on Tuesday. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15. The company has a 50 day moving average of $6.48 and a 200-day moving average of $7.40. The stock’s market capitalization is $3.54 billion.

Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.02. Opko Health had a negative return on equity of 2.13% and a negative net margin of 3.60%. The business had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. During the same quarter in the previous year, the business posted ($0.02) earnings per share. Opko Health’s quarterly revenue was up 1.8% compared to the same quarter last year. Equities research analysts predict that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Opko Health, Inc. (OPK) CEO Purchases $288,900.00 in Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/08/opko-health-inc-opk-ceo-buys-288900-00-in-stock-updated.html.

Large investors have recently added to or reduced their stakes in the company. State Street Corp increased its stake in Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after buying an additional 3,138,685 shares during the last quarter. Credit Suisse AG increased its stake in Opko Health by 122.0% in the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after buying an additional 410,445 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Opko Health during the fourth quarter valued at approximately $648,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in Opko Health during the first quarter valued at approximately $4,450,000. Finally, Paloma Partners Management Co increased its stake in Opko Health by 70.1% in the first quarter. Paloma Partners Management Co now owns 160,970 shares of the biotechnology company’s stock valued at $1,288,000 after buying an additional 66,327 shares during the last quarter. Institutional investors own 23.05% of the company’s stock.

Several research firms have recently issued reports on OPK. Jefferies Group LLC reiterated a “hold” rating and issued a $8.00 target price on shares of Opko Health in a research note on Monday, June 12th. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research note on Friday, July 21st. Barrington Research upped their target price on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $19.50 target price on shares of Opko Health in a research note on Tuesday, June 6th. Finally, BidaskClub upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Opko Health has a consensus rating of “Buy” and an average target price of $14.72.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.